OP29 Persistence Of Biologic And Targeted Synthetic Disease-Modifying Antirheumatic Drugs In The Treatment Of Rheumatoid Arthritis: A Cohort Study
Natália Brandão, Gerusa Oliveira, Marina Garcia, Bárbara Alvernaz, Francisco Acurcio, Augusto Guerra, Juliana Álvares-Teodoro · 2025
Read OP29 Persistence Of Biologic And Targeted Synthetic Disease-Modifying Antirheumatic Drugs In The Treatment Of Rheumatoid Arthritis: A Cohort Study by Natália Brandão, Gerusa Oliveira, Marina Garcia, Bárbara Alvernaz, Francisco Acurcio, Augusto Guerra, Juliana Álvares-Teodoro (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12768824.txt.
Description
Natália Brandão and co-authors wrote a 2025 study on how long patients with rheumatoid arthritis stay on modern drugs in Brazil. The joint disease is a long-term autoimmune condition. New drug classes, from lab-made antibodies to targeted pills, have changed its care, yet some patients still do not respond.
The team compared how long patients stayed on each drug class in first and second rounds of treatment. Staying on a drug is a real-world sign that it works and is tolerated. Records came from public pharmacies in Minas Gerais state, for patients who first asked for a drug between June 2018 and September 2022. Curves tracked persistence out to 18 months. The study helps officials judge which drugs serve patients best in daily practice.
Catalog record
| CREATOR | Natália Brandão, Gerusa Oliveira, Marina Garcia, Bárbara Alvernaz, Francisco Acurcio, Augusto Guerra, Juliana Álvares-Teodoro |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |